Clinical Trials

LIO-1: A phase 1b/2, Open-Label Study to evaluate the safety and efficacy of Lucitanib in Combination with Nivolumab in Patients with an advanced, metastatic Solid Tumor

Ficha Técnica

Investigador Principal

MARÍA JESÚS RUBIO PÉREZ

Promotor

CLOVIS ONCOLOGY INC

ESTADO

ACTIVO

DEPARTAMENTO

Oncología Médica

Código EudraCT: 2019-002980-81

Número protocolo: CO-3810-101

Fecha Inicio: 2021-03-10

Fecha Fin: 2023-03-30